| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Target: Isotope-Labeled Compounds / Endogenous Metabolite. 7alpha-Hydroxycholesterol is an oxysterol produced through both enzymatic (CYP7A1) and non-enzymatic oxidation of cholesterol. It is a key intermediate in the classical bile acid synthesis pathway in the liver and is also a biomarker of lipid peroxidation and oxidative stress.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
In vitro, 7alpha-Hydroxycholesterol (40 microM) increases levels of the adhesion molecules ICAM-1, VCAM-1, and E-selectin in human umbilical vein endothelial cells (HUVECs). It increases secretion of chemokine (C-C motif) ligand 2 (CCL2) and matrix metalloproteinase-9 (MMP-9) in THP-1 cells at 5 microg/mL. The labeled standard is an analytical tool, not an active compound. |
| ln Vivo |
In vivo, 7alpha-Hydroxycholesterol has been found in macrophages isolated from atherosclerotic lesions in rabbits fed a high-cholesterol diet. It is associated with pro-inflammatory effects and the progression of atherosclerosis. The labeled standard is used for quantifying these oxysterols in tissues, not for therapeutic administration.
|
| Enzyme Assay |
For cell-free assay: biological samples (plasma, liver tissue, bile) are spiked with the internal standard and subjected to lipid extraction (Folch method). After saponification or direct derivatization (e.g., trimethylsilyl (TMS) ethers), the samples are analyzed by GC-MS or LC-MS. Quantitation is based on the analyte/internal standard peak area ratio.
|
| Cell Assay |
For cell assays: endothelial cells (HUVECs) or macrophages (THP-1) are treated with the unlabeled 7alpha-Hydroxycholesterol (1-40 microM, 24-48 h) to study inflammation. The labeled standard is not used in cell-based assays for efficacy; it is added after cell lysis for LC-MS quantification of endogenous oxysterol levels in the treated cells.
|
| Animal Protocol |
For animal studies: in atherosclerosis research, rabbits or mice are fed a high-cholesterol diet, and tissues (aorta, liver) are collected. The labeled internal standard (7alpha-Hydroxycholesterol-d7) is added during sample processing to quantify the endogenous levels of 7alpha-Hydroxycholesterol and other oxysterols as biomarkers of disease progression.
|
| ADME/Pharmacokinetics |
PK properties: 7alpha-Hydroxycholesterol is an endogenous intermediate and is rapidly converted to 7alpha-hydroxy-4-cholesten-3-one by the enzyme 3beta-hydroxy-delta5-C27-steroid dehydrogenase (HSD3B7) in the bile acid synthesis pathway. It has a short half-life and does not accumulate. The labeled standard does not exhibit distinct PK behavior.
|
| Toxicity/Toxicokinetics |
No toxicity data are reported for the labeled standard. The unlabeled 7alpha-Hydroxycholesterol is a signaling molecule involved in inflammation and atherosclerosis. At high concentrations, it can induce oxidative stress and endothelial dysfunction. The labeled compound is for research use only and is considered non-hazardous for transport under normal conditions.
|
| References |
|
| Additional Infomation |
7alpha-Hydroxycholesterol-d7 is a research standard, not a drug. It is not FDA-approved for clinical use. It is used as a stable isotope-labeled internal standard (SIL-IS) for cholesterol and oxysterol measurement in clinical diagnostics, metabolic research, and quality control. The unlabeled metabolite is a key regulatory molecule in bile acid homeostasis and lipid metabolism.
|
| Molecular Formula |
C26H44O2
|
|---|---|
| Molecular Weight |
395.669500350952
|
| Exact Mass |
388.334
|
| CAS # |
349553-94-2
|
| Related CAS # |
7α-Hydroxycholesterol;566-26-7
|
| PubChem CID |
3247055
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
503.4±38.0 °C at 760 mmHg
|
| Flash Point |
211.8±21.4 °C
|
| Vapour Pressure |
0.0±2.9 mmHg at 25°C
|
| Index of Refraction |
1.539
|
| LogP |
7.41
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
29
|
| Complexity |
624
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
[2H]C([2H])([2H])C([2H])(CCC[C@@H](C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C=C4[C@@]3(CC[C@@H](C4)O)C)O)C)C([2H])([2H])[2H]
|
| InChi Key |
OYXZMSRRJOYLLO-WCYTWDCFSA-N
|
| InChi Code |
InChI=1S/C27H46O2/c1-17(2)7-6-8-18(3)21-9-10-22-25-23(12-14-27(21,22)5)26(4)13-11-20(28)15-19(26)16-24(25)29/h16-18,20-25,28-29H,6-15H2,1-5H3/t18-,20+,21-,22+,23+,24-,25+,26+,27-/m1/s1/i1D3,2D3,17D
|
| Chemical Name |
(3S,7S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6,7,7,7-tetradeuterio-6-(trideuteriomethyl)heptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,7-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5274 mL | 12.6368 mL | 25.2736 mL | |
| 5 mM | 0.5055 mL | 2.5274 mL | 5.0547 mL | |
| 10 mM | 0.2527 mL | 1.2637 mL | 2.5274 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
